Product Description
ABP1011 T is an innovative tyrosine kinase inhibitor (TKI) that effectively inhibits EGFR, c-MET, FGFR1-4, VEGFR1-3, RET, and c-KIT. Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. (Sourced from: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e15145)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Aibo Pharmaceutical Technology
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Small Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20222678 |
CTR20222678 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2025-08-25 |
2025-11-23 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07321574 |
ABP1011T-03 | P2 |
Recruiting |
Small Cell Lung Cancer |
2028-11-28 |
2% |
2026-01-08 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|